Altre lingue Skye Bioscience, Inc.

Azioni

EMBI

US83086J2006

Mercato chiuso - Nasdaq Altri mercati azionari 22:00:00 17/05/2024			Variaz. 5gg	Var. 1 gen.
12,05 ^USD	-1,63%		+6,45%	+343,01%

10/05	Skye Bioscience, Inc. riporta i risultati degli utili per il primo trimestre conclusosi il 31 marzo 2024	CI
22/03	Skye Bioscience, Inc. riporta i risultati degli utili per l'intero anno terminato il 31 dicembre 2023	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Skye Bioscience Highlights Novel Synthetic Cannabinoid-based Library Capable of Modulating the Endocannabinoid System to Treat Ocular Diseases at ARVO 2024 Annual Meeting	13/05
Skye Bioscience, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	10/05
Skye Bioscience, Inc.(NasdaqGM:SKYE) added to NASDAQ Transportation Index	23/04
Skye Bioscience, Inc.(NasdaqGM:SKYE) added to NASDAQ Composite Index	12/04
Skye Bioscience Uplists to The Nasdaq Global Market	10/04
SKYE BIOSCIENCE : AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS - Form 8-K	03/04
Skye Bioscience, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	22/03
Skye Bioscience, Inc. announced that it has received $40 million in funding	13/03
Skye Bioscience Announces $40 Million Private Placement Equity Financing	11/03
Skye Bioscience, Inc. announced that it expects to receive $40 million in funding	11/03
Skye Bioscience Appoints Dr. Annalisa Jenkins to Board of Directors	04/03
Skye Bioscience Announces Board Changes	04/03
Skye Bioscience Completes Enrollment of Phase 2a Clinical Trial of SBI-100 Ophthalmic Emulsion in Glaucoma and Ocular Hypertension	26/02
Skye Bioscience Completes Enrollment of Phase 2A Clinical Trial of SBI-100 Ophthalmic Emulsion in Glaucoma and Ocular Hypertension	26/02
Skye Bioscience, Inc. announced that it has received $49.99101 million in funding	12/02
Skye Bioscience to Present at Oppenheimer Investor Conference	07/02
Skye Bioscience Announces $50.25 Million Private Placement Equity Financing	29/01
Skye Bioscience, Inc. announced that it expects to receive $50.249992 million in funding	29/01
Skye Bioscience Receives IND Clearance for Phase 2 Clinical Trial of Nimacimab in Obesity and Chronic Kidney Disease	09/01
Skye Bioscience Responds to OTC Markets Promotional Policy	11/12

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Skye Bioscience, Inc.

Azioni

EMBI

US83086J2006

Altre lingue

Filtri